---
schema_version: "secwatch.filing_event.v1"
accession: "0001607062-21-000444"
form_type: "8-K"
ticker: "RGBP"
cik: "0001589150"
company_name: "Regen BioPharma Inc"
filed_at: "2021-10-22T23:59:59+00:00"
generated_at: "2026-06-28T18:48:09.459741+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Regen BioPharma settles convertible notes for $43,529 cash to avoid potential issuance of 855M shares

## Summary
- Settled convertible notes principal of $29,836 and accrued interest of $26,227 for $43,529.30 cash.
- Notes had a default conversion provision allowing conversion at 65% of lowest bid price during delinquency.
- Company determined provision could permit conversion even after cure, enabling up to 855,584,615 shares worth $16.6M.
- Settlement eliminates the default-conversion risk and potential massive dilution for existing shareholders.

## SEC filing metadata
- accession: 0001607062-21-000444
- form_type: 8-K
- ticker: RGBP
- cik: 0001589150
- company_name: Regen BioPharma Inc
- filed_at: 2021-10-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1589150/000160706221000444/0001607062-21-000444-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1589150/000160706221000444/rgbp102221form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001607062-21-000444
- JSON: https://secwatch.observer/filing/0001607062-21-000444.json
- Plain text: https://secwatch.observer/filing/0001607062-21-000444.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.